{
  "slug": "grail-galleri",
  "name": "GRAIL (Galleri)",
  "description": "GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. It developed the Galleri test, a multi-cancer early detection blood test that can detect a signal shared by more than 50 types of cancer with a low false positive rate.",
  "url": "https://optimly.ai/brand/grail-galleri",
  "logoUrl": "",
  "baiScore": 78,
  "archetype": "Challenger",
  "category": "Biotechnology",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [],
  "inboundCompetitors": [],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-05-07T14:27:48.756359+00:00",
  "verifiedVitals": {
    "website": "https://www.grail.com",
    "founded": "2016",
    "headquarters": "Menlo Park, California, USA",
    "pricing_model": "Enterprise/Custom (Employer plans) or Custom (approx. $949 self-pay)",
    "core_products": "Galleri (Multi-Cancer Early Detection Test)",
    "key_differentiator": "The ability to detect 50+ cancers from a single blood draw using proprietary methylation-based cfDNA technology with a <1% false positive rate.",
    "target_markets": "Healthcare systems, self-insured employers, and individuals age 50+ at elevated risk for cancer.",
    "employee_count": "1,000-5,000",
    "funding_stage": "Public (NASDAQ: GRAL)",
    "subcategory": "Genomics & Diagnostics"
  },
  "intentTags": null,
  "timestamp": 1778212463675
}